Tagar (Indian Valerian): Traditional Uses & Evidence

TL;DR

Tagar (Valeriana wallichii), or Indian valerian, is a Himalayan root drug used in Ayurveda as a sleep remedy and for epilepsy, spasms, and nervous debility. One small 2015 comparator trial (15 per arm) found Tagara Churna (4 g with milk, three times daily, one month) improved insomnia symptoms significantly versus Jatamansi: promising, but tiny, unblinded, and without a placebo arm.

What it is

Tagar is Valeriana wallichii DC., a hairy perennial herb of the Valerianaceae family growing in the temperate Himalayas from Kashmir to Bhutan at 1,300–3,800 m altitude (and the Khasi hills at 1,250–1,800 m). The rhizome (moola) is the part used medicinally (Singh et al., World J Pharm Res 2023). The review cites the Ayurvedic Pharmacopoeia of India (Part I, Vol. I) as its pharmacopoeial reference for the herb (same review). Its chemistry includes valepotriates, dihydrovaltrate, valerenic-acid-type compounds, 6-methylapigenin, hesperidin, and sesquiterpenoids (a Current Traditional Medicine 2023 review).

A critical distinction: "valerian" in Western research means the European species Valeriana officinalis. The NIH Office of Dietary Supplements notes the genus Valeriana includes over 250 species, but V. officinalis, a perennial native to Europe and Asia, is the species most often used in the United States and Europe and the only species its fact sheet covers (NIH ODS Valerian fact sheet). Trial data on V. officinalis cannot be imported as evidence for tagar.

Traditional use

V. wallichii "has been used as a sleep remedy since ancient times in the Indian traditional system of medicines," and also as a diuretic, spasmolytic, and pain-relieving agent: used for epilepsy, dyspeptic symptoms, habitual constipation, insanity, nervous debility, obesity, and spastic disorders (a Current Traditional Medicine 2023 review). A 2023 review adds that Ayurvedic texts and physicians have used it in epilepsy, skin diseases, and bleeding disorders; its paste is applied locally to fractures, rheumatoid-affected joints, and wounds. And it is regarded as an antidote for visha (poison) such as insect, scorpion, and snake bites (Singh et al., World J Pharm Res 2023). These are traditional uses, not clinical proof.

What modern research says

Human trials: one small trial

A 2015 randomized trial at an Ayurvedic hospital enrolled 34 patients with primary insomnia (ages 15–45); 30 completed treatment (15 per arm). One group received Tagara Churna: powder of V. wallichii rhizome, 4 g with milk three times daily after food for one month: and the other received Jatamansi Churna on the same schedule. The Tagara group reported statistically significant improvements (all P<0.001): sleep initiation 76.00%, sleep duration 55.17%, disturbed sleep 69.58%, and routine-work disturbances 73.95%. Both groups improved, and the between-group difference was statistically significant only for routine-work disturbances (Toolika et al., AYU 2015).

Honest limits: 15 patients per arm is tiny, both arms received active herbs (no placebo), blinding was not described, outcomes were symptom scores (Athens Insomnia Scale plus Ayurvedic symptom gradings), the trial was single-center, and the publication does not report adverse events or a systematic safety assessment. One small trial is a signal, not proof.

Preclinical findings

The Bentham review's main emphasis is the plant's anticancer potential, described through in-vitro cytotoxic and in-vivo antitumor studies (a Current Traditional Medicine 2023 review). These are laboratory and animal findings: they do not make tagar a cancer treatment, and the reviewers stress that molecular mechanisms remain to be established.

What the evidence does not support (yet)

Anxiety, epilepsy, and pain benefits are traditional indications with no human-trial backing for this species. Sleep has exactly one small, unblinded, placebo-free trial. Do not confuse tagar with European valerian products tested in Western sleep trials: and note the Bentham reviewers' call for "clinical trials" concerned the plant's anticancer potential, not its traditional sleep use.

Dosage

Two regimens appear in the sources reviewed: both are research or traditional regimens, not recommendations. In the 2015 insomnia trial, Tagara Churna (rhizome powder) was given at 4 g with milk, three times daily after food, for one month (Toolika et al., AYU 2015). A classical dose of 1.5–3 g (12–24 ratti) of root as a cold infusion or decoction is recorded in Nighantu Adarsa and cited in a 2023 review (Singh et al., World J Pharm Res 2023). No pharmacopoeial dose for V. wallichii was found in the sources reviewed. Do not borrow dosing from European valerian (V. officinalis) products: it is a different species with different chemistry.

Safety & contraindications

Human safety data for V. wallichii are sparse: the single small insomnia trial's publication does not report adverse events or a systematic safety assessment, and no dedicated safety studies were identified in the sources reviewed. The safety profile of European valerian should not be assumed to transfer across species. There are no safety data for pregnancy or breastfeeding: discuss with a qualified practitioner before any use in pregnancy. As always, discuss use with a qualified practitioner, especially if you take medicines for sleep, anxiety, or seizures.

FAQs

Is tagar the same as valerian?

No. Tagar is Valeriana wallichii, the Indian/Himalayan species used in Ayurveda. Western "valerian" products and clinical trials use the European species Valeriana officinalis. The NIH notes the genus has over 250 species but its evidence summary covers only V. officinalis (NIH ODS Valerian fact sheet; a 2023 review in Current Traditional Medicine).

Does tagar help with sleep?

Traditionally it has been used as a sleep remedy in Indian medicine (a 2023 review in Current Traditional Medicine). One small 2015 trial (30 completers) found Tagara Churna: 4 g of V. wallichii rhizome powder with milk, three times daily for a month: improved insomnia symptoms, with sleep initiation improving 76% and sleep duration 55.17% (both P<0.001). But the trial was tiny, had no placebo arm, and blinding was not described, so this is a preliminary signal rather than proof (Toolika et al., AYU 2015).

Is Indian valerian safe?

Human safety data are sparse: the one small insomnia trial's publication does not report adverse events. Do not assume the European valerian safety record applies. There are no safety data for pregnancy or breastfeeding: discuss with a qualified practitioner before use.

Why can't European valerian research be used for tagar?

Different species, different chemistry, no shared trials. The V. wallichii evidence base consists of one small insomnia trial; Western valerian trials tested V. officinalis and cannot be imported as evidence for tagar.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.